1-([1,3]恶唑并[4,5-b]吡啶-2-基)-9-十八碳炔-1-酮 | 288862-89-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶唑并吡啶类
• 中文名称: 1-([1,3]恶唑并[4,5-b]吡啶-2-基)-9-十八碳炔-1-酮
• 英文名称: 1-Oxazolo[4,5-b]pyridin-2-yl-9-octadecyn-1-one
• 英文别名: 1-([1,3]oxazolo[4,5-b]pyridin-2-yl)octadec-9-yn-1-one
• CAS: 288862-89-5
• 化学式: C₂₄H₃₄N₂O₂
• 分子量: 382.5
• InChiKey: DBMKKVSGBYKSFI-UHFFFAOYSA-N

物化性质

• 沸点：
  508.3±56.0 °C(Predicted)
• 密度：
  1.029±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：20mg/mL； DMSO：20mg/mL； DMSO:PBS (pH 7.2)(1:1)：0.15 mg/ml；乙醇：20mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  28
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  56
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• Inhibitors of fatty acid amide hydrolase
  申请人：The Scripps Research Institute

  公开号：EP2093220A2

  公开（公告）日：2009-08-26

  Improved competitive inhibitors of fatty acid amide hydrolase (FAAH) employ an alpha-keto heterocyclic pharmacophore and a binding subunit having a pi-unsaturation. The alpha-keto heterocyclic pharmacophore and a binding subunit are attached to one another, preferably by a hydrocarbon chain. The improvement lies in the use of a heterocyclic pharmacophore selected from oxazoles, oxadiazoles, thiazoles, and thiadiazoles that have alkyl or aryl substituents at their 4 and/or 5 positions. The improved competitive inhibitors of FAAH display enhanced activity over conventional competitive inhibitors of FAAH.

  改进的脂肪酸酰胺水解酶（FAAH）竞争性抑制剂采用了α-酮杂环药源和具有对不饱和度的结合亚基。α-酮杂环药基和结合亚基彼此连接，最好是通过烃链连接。改进之处在于使用了选自噁唑、噁二唑、噻唑和噻二唑的杂环嗜药体，这些杂环嗜药体的 4 和/或 5 位具有烷基或芳基取代基。与传统的 FAAH 竞争性抑制剂相比，改进的 FAAH 竞争性抑制剂显示出更强的活性。
• Neurogenesis by muscarinic receptor modulation with sabcomelin
  申请人：Braincells, Inc.

  公开号：EP2258359A2

  公开（公告）日：2010-12-08

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。
• Neurogenesis with acetylcholinesterase inhibitor
  申请人：Braincells, Inc.

  公开号：EP2258358A2

  公开（公告）日：2010-12-08

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。
• MODULATION OF NEUROGENESIS BY HDAC INHIBITION
  申请人：Braincells, Inc.

  公开号：EP1937236A2

  公开（公告）日：2008-07-02